Go Pro

Simon Baker Analyst Performance

Analyst at Rothschild & Co Redburn

Simon Baker is a stock analyst at Rothschild & Co Redburn focused in the healthcare sector, covering 7 publicly traded companies. Over the past year, Simon Baker has issued 1 stock ratings, including and sell recommendations. While full access to Simon Baker's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Simon Baker's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
8 Last 11 Years
Buy Recommendations
25.00% 2 Buy Ratings
Companies Covered
7 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy25.0%2 ratings
Hold50.0%4 ratings
Sell25.0%2 ratings

Out of 8 total stock ratings issued by Simon Baker at Rothschild & Co Redburn, the majority (50.0%) have been Hold recommendations, followed by 25.0% Buy and 25.0% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
57.1% of companies on NASDAQ
4 companies
NYSE
42.9% of companies on NYSE
3 companies

Simon Baker, an analyst at Rothschild & Co Redburn, currently covers 7 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
5 companies
71.4%
Communication Services
2 companies
28.6%

Simon Baker of Rothschild & Co Redburn specializes in stock coverage within the Healthcare sector, with additional focus on Communication Services companies.

Coverage Industries

IndustryPercentage
HEALTHCARE EQUIPMENT & SUPPLIES
2 companies
28.6%
BIOTECHNOLOGY
1 company
14.3%
PHARMACEUTICALS
1 company
14.3%
LIFE SCIENCES TOOLS & SERVICES
1 company
14.3%
MEDIA
1 company
14.3%
ENTERTAINMENT
1 company
14.3%

Simon Baker's Ratings History at Rothschild & Co Redburn

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Moderna, Inc. stock logo
MRNA
Moderna
9/3/2026Downgrade$150.81$81.00Sell